CENTAEarnings•globenewswire•
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Sentiment:Neutral (60)
Summary
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire